UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Annals of oncology, ISSN 0923-7534, 07/2012, Volume 23, Issue 7, pp. 1818 - 1825
GnRH analogues | ovarian reserve | chemotherapy | fertility | Hodgkin lymphoma | Chemotherapy | Fertility | Ovarian reserve | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Doxorubicin - therapeutic use | Multivariate Analysis | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Gonadotropin-Releasing Hormone - analogs & derivatives | Cyclophosphamide - therapeutic use | Young Adult | Bleomycin - therapeutic use | Menopause - drug effects | Vinblastine - adverse effects | Fertility - drug effects | Follicle Stimulating Hormone - blood | Hodgkin Disease - drug therapy | Adult | Female | Ovary - drug effects | Gonadotropin-Releasing Hormone - therapeutic use | Menstrual Cycle - drug effects | Anti-Mullerian Hormone - blood | Etoposide - adverse effects | Prednisone - adverse effects | Survivors | Etoposide - therapeutic use | Logistic Models | Bleomycin - adverse effects | Randomized Controlled Trials as Topic | Pregnancy | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Ovary - physiopathology | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 02/2009, Volume 27, Issue 5, pp. 805 - 811
Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Doxorubicin - therapeutic use | Dacarbazine - therapeutic use | Humans | Middle Aged | Etoposide - therapeutic use | Male | Vinblastine - therapeutic use | Cyclophosphamide - therapeutic use | Bleomycin - therapeutic use | Carboplatin - therapeutic use | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Prednisone - therapeutic use | Index Medicus
Journal Article
Paediatric drugs, ISSN 1174-5878, 2010, Volume 12, Issue 2, pp. 85 - 98
Journal Article
4.
Full Text
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Journal of clinical oncology, ISSN 0732-183X, 08/2016, Volume 34, Issue 23, pp. 2690 - +
Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Hodgkin Disease - genetics | Hodgkin Disease - pathology | Humans | Middle Aged | Male | Vinblastine - therapeutic use | Chemoradiotherapy | Mechlorethamine - therapeutic use | DNA Copy Number Variations | Young Adult | Bleomycin - therapeutic use | Adult | Female | Programmed Cell Death 1 Ligand 2 Protein - analysis | Programmed Cell Death 1 Ligand 2 Protein - genetics | Risk Factors | Etoposide - therapeutic use | In Situ Hybridization, Fluorescence | Treatment Outcome | Chromosomes, Human, Pair 9 | B7-H1 Antigen - genetics | Disease-Free Survival | Gene Amplification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Chromosome Aberrations | Vincristine - therapeutic use | Aged | B7-H1 Antigen - analysis | Neoplasm Staging | Prednisone - therapeutic use | Index Medicus | Hema16 | Hema27 | ORIGINAL REPORTS
Journal Article
5.
Emerging Agents in the Treatment of Anthracycline- and Taxane-Refractory Metastatic Breast Cancer
Seminars in oncology, ISSN 0093-7754, 04/2008, Volume 35, Issue 2, pp. S31 - S38
Life Sciences & Biomedicine | Oncology | Science & Technology | Dioxoles - therapeutic use | Glutamates - therapeutic use | Guanine - analogs & derivatives | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Drugs, Investigational - therapeutic use | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Epothilones - therapeutic use | Vinblastine - therapeutic use | Furans - therapeutic use | Deoxycytidine - therapeutic use | Diphtheria Toxin - therapeutic use | Neoplasm Metastasis | Vinblastine - analogs & derivatives | Female | Ketones - therapeutic use | Antineoplastic Agents, Phytogenic - therapeutic use | Guanine - therapeutic use | Camptothecin - therapeutic use | Clinical Trials as Topic | Tetrahydroisoquinolines - therapeutic use | Breast Neoplasms - drug therapy | Pemetrexed | Antineoplastic Agents, Alkylating - therapeutic use | Breast Neoplasms - pathology | Quinazolines - therapeutic use | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Hodgkin's disease | Index Medicus | Abridged Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 08/2014, Volume 25, Issue 8, pp. 1622 - 1628
secondary malignancy | prognostic factors | intensive chemotherapy | phase 3 trial | Hodgkin lymphoma | Intensive chemotherapy | Secondary malignancy | Phase 3 trial | Prognostic factors | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Pharmacology. Drug treatments | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Antineoplastic agents | Tumors | Doxorubicin - therapeutic use | Dacarbazine - therapeutic use | Hodgkin Disease - pathology | Humans | Middle Aged | Etoposide - therapeutic use | Male | Treatment Outcome | Vinblastine - therapeutic use | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Bleomycin - therapeutic use | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Vincristine - therapeutic use | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Neoplasm Staging | Prednisone - therapeutic use | Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 03/2011, Volume 152, Issue 5, pp. 551 - 560
ABVD | positron emission tomography | review panel | BEACOPP | Hodgkin lymphoma | Review panel | Positron emission tomography | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Hodgkin Disease - diagnostic imaging | Doxorubicin - therapeutic use | Prognosis | Dacarbazine - therapeutic use | Humans | Middle Aged | Etoposide - therapeutic use | Male | Treatment Outcome | Positron-Emission Tomography | Vinblastine - therapeutic use | Cyclophosphamide - therapeutic use | Bleomycin - therapeutic use | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Epidemiologic Methods | Vincristine - therapeutic use | Hodgkin Disease - drug therapy | Adult | Female | Drug Substitution | Prednisone - therapeutic use | Chemotherapy | Lymphomas | PET imaging | Cancer | Index Medicus | Nuclear medicine | Toxicity | Survival | Hodgkin's disease
Journal Article
The New England journal of medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 11, pp. 1015 - 1026
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Docetaxel | Neoplasm Recurrence, Local - drug therapy | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Vinblastine - therapeutic use | Paclitaxel - therapeutic use | Platinum Compounds - therapeutic use | Taxoids - therapeutic use | Urologic Neoplasms - pathology | Urologic Neoplasms - drug therapy | Vinblastine - analogs & derivatives | Antineoplastic Agents - adverse effects | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Programmed Cell Death 1 Receptor - immunology | Urothelium | Adenocarcinoma | Care and treatment | Cancer patients | Health aspects | Urothelial cancer | Cell survival | PD-1 protein | Tumor cells | Metastasis | Patients | Pembrolizumab | Chemotherapy | Platinum | Medical prognosis | PD-L1 protein | Paclitaxel | Ligands | Death | Urothelial carcinoma | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 10/2019, Volume 134, Issue 15, pp. 1238 - 1246
Hodgkin Disease - diagnostic imaging | Procarbazine - administration & dosage | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Dacarbazine - therapeutic use | Hodgkin Disease - pathology | Humans | Middle Aged | Male | Vinblastine - administration & dosage | Vinblastine - therapeutic use | Cyclophosphamide - therapeutic use | Neoplasm Staging - methods | Young Adult | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - administration & dosage | Etoposide - therapeutic use | Bleomycin - administration & dosage | Positron-Emission Tomography - methods | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - therapeutic use | Prednisone - therapeutic use | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia | 8 | 39
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 10/2005, Volume 23, Issue 30, pp. 7555 - 7564
Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Biological and medical sciences | Medical sciences | Non tumoral diseases | Tumors | Female genital diseases | Doxorubicin - therapeutic use | Age Factors | Dacarbazine - therapeutic use | Humans | Middle Aged | Menstrual Cycle | Male | Vinblastine - therapeutic use | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Contraceptives, Oral | Bleomycin - therapeutic use | Amenorrhea - etiology | Hodgkin Disease - drug therapy | Adult | Female | Risk Factors | Etoposide - therapeutic use | Treatment Outcome | Combined Modality Therapy | Disease-Free Survival | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - therapeutic use | Aged | Neoplasm Staging | Prednisone - therapeutic use | Index Medicus
Journal Article
American journal of clinical oncology, ISSN 0277-3732, 02/2015, Volume 38, Issue 1, pp. 68 - 73
chemoradiotherapy | autologous stem cell transplantation | Hodgkin lymphoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Methylprednisolone - therapeutic use | Cytarabine - therapeutic use | Dacarbazine - therapeutic use | Hodgkin Disease - pathology | Humans | Middle Aged | Male | Transplantation, Autologous | Melphalan - therapeutic use | Vinblastine - therapeutic use | Neoplasm Recurrence, Local - pathology | Young Adult | Carmustine - therapeutic use | Bleomycin - therapeutic use | Carboplatin - therapeutic use | Mediastinal Neoplasms - therapy | Adult | Female | Retrospective Studies | Chemoradiotherapy - methods | Ifosfamide - therapeutic use | Neoplasm Recurrence, Local - therapy | Etoposide - therapeutic use | Treatment Outcome | Dexamethasone - therapeutic use | Stem Cell Transplantation - methods | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology | Hodgkin Disease - therapy | Adolescent | Neoplasm Staging | Cohort Studies | Index Medicus
Journal Article